For the quarter ending 2026-03-31, MRVI made $65,837K in revenue. -$3,733K in net income. Net profit margin of -5.67%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 65,837 | 49,866 | 41,630 | 47,397 |
| Cost of revenue | 32,136 | 37,024 | 35,975 | 39,629 |
| Gross profit | 33,701 | -65,912 | 5,655 | - |
| Selling, general and administrative | 29,092 | 31,583 | 35,396 | 38,575 |
| Research and development | 3,889 | 3,788 | 3,844 | 4,882 |
| Change in estimated fair value of contingent consideration | - | -100* | 60 | 140 |
| Goodwill impairment | 0 | - | 0 | 30,449 |
| Impairment of goodwill and long-lived assets | - | -49,136* | - | - |
| Restructuring | 2,878 | 6,748* | 7,386 | 0 |
| Total operating expenses | 35,859 | -7,117 | 46,686 | 113,675 |
| Loss from operations | -2,158 | -58,795 | -41,031 | -66,278 |
| Interest expense | 5,749 | 6,555 | 6,844 | 6,815 |
| Interest income | 1,873 | 2,384 | 2,797 | 3,030 |
| Loss on extinguishment of debt | - | 0* | - | - |
| Change in payable to related parties pursuant to the tax receivable agreement | - | 0* | 0 | - |
| Other (expense) income | -494 | -43 | -71 | -4,062 |
| Loss before income taxes | -6,528 | -63,009 | -45,149 | -74,125 |
| Income tax (benefit) expense | -151 | 6 | -92 | -4,288 |
| Net loss | -6,377 | -63,015 | -45,057 | -69,837 |
| Net loss attributable to non-controlling interests | -2,644 | -27,334 | -19,501 | -30,246 |
| Net loss attributable to maravai lifesciences holdings, inc | -3,733 | -35,681 | -25,556 | -39,591 |
| Basic EPS | -0.02 | -0.246 | -0.18 | -0.27 |
| Diluted EPS | -0.02 | -0.246 | -0.18 | -0.27 |
| Basic Average Shares | 146,426,000 | 145,096,000 | 144,683,000 | 144,236,000 |
| Diluted Average Shares | 146,426,000 | 145,096,000 | 144,683,000 | 144,236,000 |
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)